Law360, New York (May 08, 2012, 7:56 PM ET) -- Gilead Sciences Inc.'s Truvada, an antiretroviral drug widely used in HIV treatment, is effective at preventing HIV infection in at-risk individuals, according to a U.S. Food and Drug Administration report released Tuesday.
In two separate trials, Truvada's combination of tenofovir and emtricitabine taken as a pre-exposure prophylaxis greatly decreased rates of infection in individuals with HIV-infected sexual partners, according to the report.
The FDA's Antiviral Drugs Advisory Committee on Friday will consider Gilead's request to sell Truvada as a preventive treatment, which has been granted priority...
Gilead's Truvada May Cut HIV Infection Risk, FDA Says
To view the full article, take a free trial now.
